| Program |
Preclinical |
Phase I |
Phase II |
Phase III |
|
SGN-40 |
Diffuse large B-cell lymphoma (DLBCL) |
|
|
DLBCL (Rituxan-ICE +/- SGN-40) |
|
|
DLBCL (+Rituxan/Gemzar) |
|
|
|
Non-Hodgkin lymphoma (NHL) (+Rituxan) |
|
|
|
Multiple myeloma (+Revlimid) |
|
|
|
Multiple myeloma (+Velcade) |
|
|
SGN-33
(lintuzumab) |
Acute myeloid leukemia (AML)
(low-dose cytarabine +/- SGN-33) |
|
| AML,
myelodysplastic syndromes (MDS) |
|
|
| MDS
(+Revlimid) |
|
|
|
SGN-35 |
Hodgkin lymphoma, CD30+ hematologic malignancies (every 3 week dosing) |
|
|
|
Hodgkin lymphoma, CD30+ hematologic malignancies (weekly dosing) |
|
|
|
SGN-70 |
Autoimmune diseases |
|
|
|
SGN-75 |
Solid tumors,
CD70+ hem. malignancies |
|
|
|
| Anti-CD19 ADC |
CD19+ hem.
malignancies |
|
|
|
| Engineered monoclonal antibody |
|
| Antibody-drug conjugate
(ADC) |
|